Publications by authors named "Michael Messig"

Claim this Profile
C
Corrections to: Once-daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study.
Lesley M Arnold, Pierre Arsenault, Cynthia Huffman, Jeffrey Patrick, Michael Messig

Curr Med Res Opin· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).
Benoit J Arsenault, Payal Kohli, Gilles Lambert, David A DeMicco, Rachel Laskey, Michael M Messig

Am J Cardiol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.
Denise Black, Michael Messig, Ching-Ray Yu, Annlouise R Assaf, Barry S Komm

Menopause· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
James Shepherd, Andrei Breazna, Prakash C Deedwania, John C LaRosa, Nanette K Wenger, Michael Messig

Am J Cardiol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder.
Philip T Ninan, Jeff Musgnung, Michael Messig, Gina Buckley, Christine J Guico-Pabia

Prim Care Companion CNS Disord· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL.
Payal Kohli, David D Waters, Rita Nemr, Benoit J Arsenault, Michael Messig

J Am Coll Cardiol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study.
Lesley M Arnold, Pierre Arsenault, Cynthia Huffman, Jeffrey L Patrick, Michael Messig

Curr Med Res Opin· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Pierre Amarenco, Alfred Callahan, Vito M Campese, Larry B Goldstein, Michael G Hennerici, Michael Messig

Stroke· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
Lucy Abraham, JoAnn V Pinkerton, Michael Messig, Kelly A Ryan, Barry S Komm

Maturitas· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d.
Arif Khan, Jeff Musgnung, Tanya Ramey, Michael Messig, Gina Buckley

J Clin Psychopharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial.
Philip Raskin, Cynthia Huffman, Cory Toth, Michael J Asmus, Michael Messig

Clin J Pain· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).
Kwok-Leung Ong, David D Waters, Michael Messig, David A DeMicco, Kerry-Anne Rye

Am J Cardiol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
Bruce Ovbiagele, Larry B Goldstein, Pierre Amarenco, Michael Messig, Henrik Sillesen

J Stroke Cerebrovasc Dis· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of deferring a quit attempt with smoking cessation success: a secondary analysis.
John R Hughes, Cristina Russ, Michael A Messig

J Subst Abuse Treat· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Patrick Rossignol, Daniela Dobre, John J V McMurray, Karl Swedberg, Henry Krum, Michael Messig

Circ Heart Fail· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
David D Waters, Jennifer E Ho, S Matthijs Boekholdt, David A DeMicco, John J P Kastelein, Michael Messig

J Am Coll Cardiol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2.
Raul D Santos, David D Waters, Lisa Tarasenko, Michael Messig, J Wouter Jukema

Atherosclerosis· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease.
Vera Bittner, Nanette K Wenger, David D Waters, David A DeMicco, Michael Messig

Am Heart J· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of lipid profiles and attainment of lipid goals in patients <65 years versus patients ≥65 years (from the Lipid Treatment Assessment Project [L-TAP] 2).
Fatima Rodriguez, Raul D Santos, Michael Messig, Lisa Tarasenko, Jean Ferrières

Am J Cardiol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies.
Kuan Gandelman, Gordon L Fung, Michael Messig, Rachel Laskey

Am J Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study.
Christina Gratziou, Konstantinos Gourgoulianis, Paraskevi Argyropoulou Pataka, Georgia D Sykara, Michael Messig

Tob Induc Dis· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2).
Cheng-Wen Chiang, Raul D Santos, David D Waters, Michael Messig, Lisa Tarasenko

Am J Cardiol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Gregory G Schwartz, Bernard R Chaitman, Jeffrey J Goldberger, Michael Messig

Am Heart J· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study.
Hedwig Boudrez, Christina Gratziou, Michael Messig, Michael Metcalfe

Curr Med Res Opin· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial.
Karl Fagerström, Hans Gilljam, Michael Metcalfe, Serena Tonstad, Michael Messig

BMJ· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis